Hepatology Communications
Scope & Guideline
Advancing liver health through innovative research.
Introduction
Aims and Scopes
- Liver Disease Mechanisms and Pathophysiology:
Research exploring the cellular and molecular mechanisms underlying various liver diseases, including nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), hepatitis, and hepatocellular carcinoma (HCC). - Clinical Management and Therapeutics:
Studies focused on the clinical management strategies for liver diseases, including the effectiveness and safety of pharmacological treatments, surgical interventions, and emerging therapies. - Epidemiology and Public Health:
Research investigating the epidemiological trends, risk factors, and public health implications of liver diseases on a global scale. - Innovative Diagnostic Approaches:
Development and validation of novel diagnostic tools and biomarkers to enhance the detection and monitoring of liver diseases. - Patient-Centered Care and Quality of Life:
Investigations into how liver diseases affect patients' quality of life, including psychosocial aspects and health-related quality of life outcomes. - Translational Research and Experimental Models:
Utilization of experimental models and translational research approaches to understand liver pathophysiology and to develop new therapeutic strategies.
Trending and Emerging
- Metabolic Dysfunction-Associated Liver Disease (MASH/MASLD):
Research on metabolic dysfunction-associated steatotic liver disease is gaining traction, reflecting the increasing prevalence of obesity-related liver conditions. - Immunotherapy and Targeted Therapies:
There is a growing interest in the role of immunotherapy and targeted treatments for liver cancer, particularly hepatocellular carcinoma, highlighting advancements in personalized medicine. - Gut-Liver Axis Research:
Studies exploring the gut-liver axis, including the impact of gut microbiota on liver health and disease progression, are emerging as a significant area of investigation. - Digital Health and Telemedicine:
The integration of digital health technologies and telemedicine in liver disease management is on the rise, particularly in response to the COVID-19 pandemic. - Health Disparities and Social Determinants of Health:
Research addressing health disparities in liver disease, particularly among marginalized populations, is becoming increasingly prominent as awareness grows. - Artificial Intelligence and Machine Learning:
The application of AI and machine learning in diagnosing liver diseases and predicting outcomes is a rapidly growing area, reflecting technological advancements.
Declining or Waning
- Traditional Risk Factors for Liver Disease:
There appears to be a waning emphasis on traditional risk factors for liver disease, such as obesity and alcohol consumption, as newer studies focus on metabolic dysfunction and genetic predispositions. - Conventional Biomarker Studies:
Research centered on established biomarkers for liver disease is decreasing, as innovative diagnostic methods and multi-omics approaches gain prominence. - Single Disease Focus Studies:
There is a noticeable decline in studies that focus exclusively on single liver diseases; instead, there is a shift towards comprehensive studies that address multiple liver conditions and their interrelationships. - Invasive Diagnostic Procedures:
The use of invasive diagnostic procedures, such as liver biopsies, is decreasing in favor of non-invasive methods like elastography and blood-based biomarkers.
Similar Journals
International Journal of Hepatology
Advancing liver health through open-access research.The International Journal of Hepatology, published by HINDAWI LTD, is a premier open-access journal dedicated to the field of hepatology. Since its inception, this journal has championed the dissemination of cutting-edge research and reviews pertaining to liver health, diseases, and therapies. With an ISSN of 2090-3448, the journal has been committed to open-access publishing since 2011, ensuring that vital knowledge is readily available to researchers, clinicians, and students worldwide. Based in Egypt, this journal stands out in its category, achieving a Q3 ranking in 2023 within the scope of Hepatology by Scopus, which ranks it #43 out of 82 in the field. The International Journal of Hepatology offers a platform for significant findings and discussions that influence clinical practices and foster new research directions, thus playing a crucial role in advancing the understanding of liver diseases and their management.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Pioneering research for a healthier digestive future.Welcome to the JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, an esteemed publication in the field of gastroenterology and hepatology, proudly published by WILEY. Established in 1986, this journal serves as a crucial platform for researchers, healthcare professionals, and students, presenting groundbreaking research and comprehensive reviews that drive advances in understanding and treating gastrointestinal and liver diseases. With a strong reputation evidenced by its Q1 ranking in gastroenterology and Q2 ranking in hepatology, this journal ranks impressively in the Scopus metrics - positioned at #22 out of 167 in gastroenterology and #21 out of 82 in hepatology, reflecting its contribution to scholarly excellence. Although it does not offer open access options, the journal’s rich archive and diverse topics make it indispensable for those dedicated to improving patient outcomes in these critical areas of medicine. Whether you are a seasoned researcher or an aspiring medical professional, engaging with this journal will keep you at the forefront of the latest developments and emerging trends in gastroenterology and hepatology research.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Unveiling Breakthroughs in Gastrointestinal TherapeuticsALIMENTARY PHARMACOLOGY & THERAPEUTICS, published by Wiley, is a premier scholarly journal in the fields of gastroenterology, hepatology, and pharmacology. With an impressive impact factor and ranking in the top quartile (Q1) of its classifications, the journal is recognized for its rigorous peer-reviewed research and comprehensive reviews, aiming to advance the understanding of therapeutic interventions in gastrointestinal and liver diseases. Since its inception in 1987, it has become an essential resource for researchers, healthcare professionals, and students alike, fostering scientific dialogue and innovation. With a Scopus rank placing it in the 97th percentile for pharmacology and 96th for gastroenterology, it is dedicated to publishing the most significant and impactful findings in the field. ALIMENTARY PHARMACOLOGY & THERAPEUTICS thus plays a vital role in shaping the future of medical treatments and interventions in gastrointestinal health.
Gastrointestinal Disorders
Advancing Gastrointestinal Health Through Open Access ResearchGastrointestinal Disorders is a prominent open-access journal published by MDPI, based in Switzerland, that focuses on the latest research and innovations in the fields of gastroenterology, hepatology, and immunology. Since its inception in 2019, the journal has provided a vital platform for researchers and professionals to disseminate their findings, engaging with a global audience keen on advancing knowledge in gastrointestinal health. With a dedicated commitment to high-quality, peer-reviewed articles, Gastrointestinal Disorders has gained recognition in 2023, achieving Q3 status in gastroenterology and notable rankings in several other categories, including a respectable position in the quartiles for hepatology, immunology, and oncology. Despite its recent establishment, the journal has quickly become a valuable resource, facilitating open access to critical insights in the study of gastrointestinal diseases and their management, ensuring that emerging research is readily available to inform clinical practice and educate future professionals.
Journal of Gastrointestinal and Liver Diseases
Exploring Innovations in Digestive MedicineThe Journal of Gastrointestinal and Liver Diseases, published by MEDICAL UNIV PRESS in Romania, serves as a pivotal platform for the dissemination of significant research in the fields of gastroenterology and hepatology. Established in 2006, this journal has evolved over the years, currently holding a Q3 rank in Gastroenterology and a Q2 rank in Medicine (miscellaneous), reflecting its commitment to high-quality scholarship and impactful contributions to medical science.
With an ISSN of 1841-8724 and an E-ISSN of 1842-1121, the journal engages a diverse readership of researchers, clinicians, and students passionate about advancing knowledge in gastrointestinal and liver health. While it currently does not operate under an open access model, the journal remains a vital resource for those seeking to stay updated on the latest developments and emerging trends in the field. As it converges towards a broader impact, projected through its coverage until 2024, the Journal of Gastrointestinal and Liver Diseases continues to contribute to the academic landscape, encouraging innovation and comprehensive understanding in digestive health.
DIGESTIVE AND LIVER DISEASE
Bridging research and practice in gastroenterology.DIGESTIVE AND LIVER DISEASE is a prominent journal published by Elsevier Science Inc, dedicated to advancing the field of gastroenterology and hepatology. With an ISSN of 1590-8658 and an E-ISSN of 1878-3562, this journal has established itself as a significant resource within the academic community, especially considering its Q2 ranking in both gastroenterology and hepatology categories as of 2023. Spanning from 2000 to 2024, the journal presents a diverse array of peer-reviewed articles, clinical studies, and review papers that explore the latest advancements and research findings in digestive and liver diseases. The journal's robust impact, reflected in its Scopus rankings—40th out of 167 in gastroenterology and 28th out of 82 in hepatology—highlights its critical role in shaping practices and understanding in these vital areas of medicine. With open access options available, DIGESTIVE AND LIVER DISEASE aims to make high-quality research accessible to a wider audience, thereby encouraging collaboration and innovation. Researchers, healthcare professionals, and students alike will find valuable insights into the complex mechanisms, diagnostics, and therapeutic strategies pertinent to digestive and liver health.
Journal of Clinical and Experimental Hepatology
Unveiling the latest in liver research and treatment.The Journal of Clinical and Experimental Hepatology, published by Elsevier - Division Reed Elsevier India Pvt Ltd, is a premier platform dedicated to advancing the field of hepatology. With an ISSN of 0973-6883 and an E-ISSN of 2213-3453, this journal has gained recognition for its impactful contributions to both clinical practice and scientific research in the domain of liver health. Ranking in the Q2 quartile for Hepatology in 2023 and positioned at 33rd out of 82 in Scopus’s Hepatology category, it reflects a robust impact factor and a commitment to publishing high-quality, peer-reviewed articles. Researchers, clinicians, and students can engage with a wealth of open-access content covering the latest advancements, challenges, and insights in hepatology, as the journal aims to disseminate knowledge from 2011 through 2025. Join the community of experts as we explore critical developments in the understanding and treatment of liver diseases.
Journal of Clinical and Translational Hepatology
Uniting research and clinical excellence in hepatology.Journal of Clinical and Translational Hepatology is an esteemed publication dedicated to advancing the field of hepatology through innovative research and clinical insights. Published by XIA & HE PUBLISHING INC, this journal connects researchers and healthcare professionals in the exploration of liver diseases and their management. With an impact factor that reflects its significant contribution to the discipline, the Journal holds a commendable Q2 classification in Hepatology as of 2023, and it ranks highly in both Gastroenterology and Hepatology categories on Scopus, positioning it within the top 80th percentile of its field. Although the journal is not open access, it provides its audience with invaluable information, encouraging collaboration that aims to translate clinical findings into transformative patient care. With a publication history spanning from 2013 to 2024, the Journal of Clinical and Translational Hepatology has established itself as a vital resource for researchers, clinicians, and students alike, making it a prominent voice in the hepatological community.
LIVER INTERNATIONAL
Innovating liver research for a healthier tomorrow.LIVER INTERNATIONAL, with its ISSN 1478-3223 and E-ISSN 1478-3231, is a prestigious peer-reviewed journal published by Wiley in the United Kingdom. Established in 2003, it focuses on advancing the field of hepatology, covering a broad spectrum of topics including liver disease, hepatocellular carcinoma, and transplantation. Ranking #10 out of 82 in the Scopus category for Medicine - Hepatology and boasting a remarkable 88th percentile, LIVER INTERNATIONAL has secured its reputation as a leading journal, recognized as Q1 in the 2023 category quartiles. The journal emphasizes accessibility, offering an open access option to ensure that critical research findings reach a wider audience. By facilitating the dissemination of high-quality research, LIVER INTERNATIONAL plays a vital role in shaping contemporary hepatological discourse and bridging academic inquiry with clinical practice, making it an essential resource for researchers, healthcare professionals, and students alike.
Hepatitis Monthly
Exploring the frontiers of viral hepatitis understanding.Hepatitis Monthly, published by BRIEFLAND in the Netherlands, is a pivotal journal in the fields of hepatology and infectious diseases. Established in 2007, it continues to make significant contributions to the understanding and management of hepatitis and related viral infections with a publication timeline extending through to 2024. Aiming to disseminate high-quality research, the journal serves as a forum for groundbreaking studies and innovations essential for healthcare professionals, researchers, and students alike. While it currently holds Q4 rankings in both hepatology and infectious disease categories, its ongoing commitment to addressing pressing health issues makes it an important resource in the academic community. Although it operates under a traditional access model, Hepatitis Monthly not only publishes original research articles, reviews, and case studies but also encourages the exchange of knowledge that helps shape future research directions and clinical practices. As it continues to explore the complexities surrounding viral hepatitis, this journal invites researchers to contribute to its mission of advancing scientific understanding and improving patient care.